We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Allarity Therapeutics, Inc. (ALLR - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Allarity Therapeutics, Inc. is a member of the Medical sector. This group includes 888 individual stocks and currently holds a Zacks Sector Rank of #8. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Allarity Therapeutics, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ALLR's full-year earnings has moved 1% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, ALLR has moved about 56.5% on a year-to-date basis. In comparison, Medical companies have returned an average of -8%. This means that Allarity Therapeutics, Inc. is performing better than its sector in terms of year-to-date returns.
Bioventus (BVS - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 9%.
In Bioventus' case, the consensus EPS estimate for the current year increased 24% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Allarity Therapeutics, Inc. belongs to the Medical - Biomedical and Genetics industry, which includes 431 individual stocks and currently sits at #149 in the Zacks Industry Rank. Stocks in this group have lost about 4.7% so far this year, so ALLR is performing better this group in terms of year-to-date returns.
In contrast, Bioventus falls under the Medical - Drugs industry. Currently, this industry has 135 stocks and is ranked #106. Since the beginning of the year, the industry has moved -11%.
Investors interested in the Medical sector may want to keep a close eye on Allarity Therapeutics, Inc. and Bioventus as they attempt to continue their solid performance.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Allarity Therapeutics, Inc. (ALLR - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Allarity Therapeutics, Inc. is a member of the Medical sector. This group includes 888 individual stocks and currently holds a Zacks Sector Rank of #8. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Allarity Therapeutics, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ALLR's full-year earnings has moved 1% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, ALLR has moved about 56.5% on a year-to-date basis. In comparison, Medical companies have returned an average of -8%. This means that Allarity Therapeutics, Inc. is performing better than its sector in terms of year-to-date returns.
Bioventus (BVS - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 9%.
In Bioventus' case, the consensus EPS estimate for the current year increased 24% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Allarity Therapeutics, Inc. belongs to the Medical - Biomedical and Genetics industry, which includes 431 individual stocks and currently sits at #149 in the Zacks Industry Rank. Stocks in this group have lost about 4.7% so far this year, so ALLR is performing better this group in terms of year-to-date returns.
In contrast, Bioventus falls under the Medical - Drugs industry. Currently, this industry has 135 stocks and is ranked #106. Since the beginning of the year, the industry has moved -11%.
Investors interested in the Medical sector may want to keep a close eye on Allarity Therapeutics, Inc. and Bioventus as they attempt to continue their solid performance.